retatrutide compound Demand for Unapproved Weight-Loss Drug Surges on Social Media Retatrutide

Results announced in December 2025 confirmed the Phase 2 findings at a longer timepoint (Lilly Press Release, Dec 2025): The 28.7% weight loss at 68 weeks exceeds both semaglutide (~15% in STEP trials) and tirzepatide (~22.5% in SURMOUNT trials) at similar timepoints

Individuals on GLP-1 therapy may also practice unintended intermittent fasting, due to not being hungry

How do GLP-1 injections reduce appetite and cravings

A 20 mg vial becomes more practical at higher maintenance doses (8-12 mg/week) where a 10 mg vial would be consumed in one to two sessions

People taking the GLP-1 pill may experience some of the most commonly reported side effects, such as: The Wegovy manufacturer also lists the following commonly reported side effects: headache fatigue dizziness bloating belching gas stomach flu heartburn runny nose sore throat low blood sugar in those with type 2 diabetes It notes that people will react differently to taking Wegovy and advises people to work with a healthcare professional to help them manage any side effects they experience

This article will review the occurrence of GI AEs across different GLP-1 RAs and will outline current methods for their management